Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study

Hiroki Ishihara(Tokyo Women's Medical University), Toshio Takagi(Tokyo Women's Medical University), Hidekazu Tachibana, Hirohito Kobayashi(Ebina General Hospital), Kazuhiko Yoshida(Tokyo Women's Medical University Hospital), Tsunenori Kondo(Tokyo Women's Medical University Adachi Medical Center), Hironori Fukuda(Tokyo Women's Medical University), Takashi Ikeda(Tokyo Women's Medical University), Yasunobu Hashimoto, Yuki Nemoto(Tokyo Women's Medical University Adachi Medical Center), Hiroaki Shimmura(Jyoban Hospital of Tokiwa Foundation), Junpei Iizuka(Tokyo Women's Medical University), Kazutaka Nakamura(Tokyo Women's Medical University Hospital)
Targeted Oncology
March 1, 2023
Cited by 19


Related Papers